Girl Dies in China Gene-Editing Trial
A six-year-old girl in Shanghai died after receiving an experimental gene-editing treatment in March 2025. The therapy was a brain-directed base-editing procedure intended to address a rare neurodevelopmental mutation.
The treatment took place at Shanghai Xinhua Hospital and was part of an investigator-led clinical trial. Her family reportedly contributed about $860,000 toward the therapy’s development and clinical work. The girl developed severe immune complications days later and died after being admitted to intensive care.
The case has raised broader concerns about trial safeguards, regulatory oversight, and transparency in China’s fast-growing biotechnology sector. Investigations by media outlets and later by Chinese authorities followed the disclosure of the death.
Key Events
- A 6-year-old girl in Shanghai received an experimental gene-editing therapy at Xinhua Hospital in March 2025.
- The treatment was designed to correct a rare neurodevelopmental mutation affecting her brain development.
- Her family helped fund the therapy with about $860,000.
- She developed severe complications days after the infusion and died.
- A joint investigation later raised questions about safety, disclosure, and regulatory oversight.
- Chinese authorities and institutions launched investigations after the death became public.